Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn, Shukui Qin, Masafumi Ikeda, +17

New England Journal of Medicine

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle, Richard S. Finn, Shukui Qin, +17

The Lancet Oncology

Patient-reported OutcomesHepatologyMedicineClinical TrialsPathology +9

IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)

Ann‐Lii Cheng, S. Qin, Masafumi Ikeda, +16

Annals of Oncology

Ph Iii StudyHepatologyMedicinePathologyPharmacotherapy +8

Expression of hypoxia-inducible factor-1 alpha and associated proteins in pancreatic ductal adenocarcinoma and their impact on prognosis

Hongcheng Sun, Zhengjun Qiu, Jun Liu, +5

International Journal of Oncology

Tumor BiologyHypoxia-inducible Factor-1 AlphaOncologyPancreatic CancerMedicine +13

Clinical significance of AXL kinase family in gastric cancer.

Chew-Wun Wu, Anna F.-Y. Li, Chin‐Wen Chi, +5

PubMed

Dyskerin Overexpression in Human Hepatocellular Carcinoma Is Associated with Advanced Clinical Stage and Poor Patient Prognosis

Bei Liu, Jinglei Zhang, Chen Huang, +1

PLoS ONE

Establishment and Implementation of an Enhanced Recovery After Surgery (ERAS) Pathway Tailored for Minimally Invasive Transforaminal Lumbar Interbody Fusion Surgery

Chencheng Feng, Yaqing Zhang, Fanli Chong, +10

World Neurosurgery

Pathway TailoredEnhanced RecoveryLumbar SpineSpinal Cord InjurySpinal Fusion +3

Human Gastric Cancer Kinase Profile and Prognostic Significance of MKK4 Kinase

Chew-Wun Wu, Anna F.-Y. Li, Chin‐Wen Chi, +4

American Journal Of Pathology

MedicineReceptor Tyrosine KinaseGastroenterologyPathologyCancer Genomics +7

Patient-reported outcomes (PROs) from the Phase III IMbrave150 trial of atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (sor) as first-line treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC).

Peter R. Galle, Richard S. Finn, Shukui Qin, +16

Journal of Clinical Oncology

Patient-reported OutcomesClinical EndpointPathologyFirst-line TreatmentPharmacotherapy +22

Pt3R5G inhibits colon cancer cell proliferation through inducing ferroptosis by down-regulating SLC7A11

Lin Han, Yamei Yan, Meiyang Fan, +11

Life Sciences

Cancer ResearchSignaling PathwayMedicineCancer Cell BiologyDown-regulating Slc7a11 +6